BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 27546601)

  • 1. Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.
    Iwata T; Yoshida S; Fujiwara T; Wada H; Nakajima T; Suzuki H; Yoshino I
    Ann Thorac Surg; 2016 Dec; 102(6):1905-1910. PubMed ID: 27546601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis.
    Iwata T; Yoshida S; Nagato K; Nakajima T; Suzuki H; Tagawa T; Mizobuchi T; Ota S; Nakatani Y; Yoshino I
    Surg Today; 2015 Oct; 45(10):1263-70. PubMed ID: 25412984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis.
    Sekihara K; Aokage K; Miyoshi T; Tane K; Ishii G; Tsuboi M
    Surg Today; 2020 Aug; 50(8):905-911. PubMed ID: 32144483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
    Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
    Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis.
    Kanayama M; Mori M; Matsumiya H; Taira A; Shinohara S; Kuwata T; Imanishi N; Yoneda K; Kuroda K; Tanaka F
    Surg Today; 2020 May; 50(5):469-474. PubMed ID: 31773277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
    Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
    Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan.
    Kondoh Y; Taniguchi H; Ebina M; Azuma A; Ogura T; Taguchi Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T
    Respir Investig; 2015 Nov; 53(6):271-8. PubMed ID: 26521104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Miura Y; Saito T; Tanaka T; Takoi H; Yatagai Y; Inomata M; Nei T; Saito Y; Gemma A; Azuma A
    Respir Investig; 2018 Jan; 56(1):72-79. PubMed ID: 29325685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
    Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
    Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
    Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
    Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
    Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer.
    Mizuno Y; Iwata H; Shirahashi K; Takamochi K; Oh S; Suzuki K; Takemura H
    Eur J Cardiothorac Surg; 2012 Jun; 41(6):e161-5. PubMed ID: 22504895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
    Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
    Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful resection of lung cancer with idiopathic pulmonary fibrosis treated by pirfenidone during perioperative period].
    Shomura S; Katayama Y; Kusagawa H; Komada T
    Kyobu Geka; 2013 Sep; 66(10):890-3. PubMed ID: 24008638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
    Sakamoto S; Itoh T; Muramatsu Y; Satoh K; Ishida F; Sugino K; Isobe K; Homma S
    Intern Med; 2013; 52(22):2495-501. PubMed ID: 24240787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative use of pirfenidone and reduced risk of postoperative severe respiratory complications in patients with idiopathic pulmonary fibrosis: Propensity score-matched analysis using a nationwide database in Japan.
    Urushiyama H; Jo T; Hasegawa W; Ando T; Sakamoto Y; Uda K; Matsui H; Fushimi K; Yasunaga H; Nagase T
    Respirology; 2021 Jun; 26(6):590-596. PubMed ID: 33870611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical Outcomes of Lung Cancer Patients with Combined Pulmonary Fibrosis and Emphysema and Those with Idiopathic Pulmonary Fibrosis without Emphysema.
    Sato S; Koike T; Hashimoto T; Ishikawa H; Okada A; Watanabe T; Tsuchida M
    Ann Thorac Cardiovasc Surg; 2016 Aug; 22(4):216-23. PubMed ID: 27052999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.